Emergent BioSolutions EBS announced today the initiation of
a Phase 1b study (Protocol 16009) of TRU-016 in combination with
rituximab for patients with previously untreated chronic lymphocytic
leukemia (CLL). TRU-016 is a humanized anti-CD37 mono-specific protein
therapeutic in development for the treatment of B-cell malignancies.
“Preclinical studies have shown increased anti-tumor activity for the
combination of TRU-016 and rituximab beyond the levels achieved when
either drug was administered alone,” said Scott C. Stromatt, M.D.,
Senior Vice President and Chief Medical Officer, Emergent BioSolutions.
“We look forward to clinical evaluation of the effect of TRU-016 in
combination with rituximab in previously untreated CLL patients.”
The Phase 1b,
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in